[go: up one dir, main page]

RU2011112781A - IMMUNOMODULATING EXTRACTS FROM THE LACTOBACILLUS BACTERIA, METHODS FOR PRODUCING AND USING THEM - Google Patents

IMMUNOMODULATING EXTRACTS FROM THE LACTOBACILLUS BACTERIA, METHODS FOR PRODUCING AND USING THEM Download PDF

Info

Publication number
RU2011112781A
RU2011112781A RU2011112781/15A RU2011112781A RU2011112781A RU 2011112781 A RU2011112781 A RU 2011112781A RU 2011112781/15 A RU2011112781/15 A RU 2011112781/15A RU 2011112781 A RU2011112781 A RU 2011112781A RU 2011112781 A RU2011112781 A RU 2011112781A
Authority
RU
Russia
Prior art keywords
lactobacillus
extract
extract according
bacterial strains
bacterial
Prior art date
Application number
RU2011112781/15A
Other languages
Russian (ru)
Other versions
RU2500412C2 (en
Inventor
Жак Ален БОЕР (CH)
Жак Ален БОЕР
Марко САЛЬВАНЬИ (CH)
Марко САЛЬВАНЬИ
Жан-Пьер Леон ВИГРУ (FR)
Жан-Пьер Леон ВИГРУ
Летисия Леела Жизель ШАЛВЕ (FR)
Летисия Леела Жизель ШАЛВЕ
Карло КЬЯВАРОЛИ (FR)
Карло КЬЯВАРОЛИ
Original Assignee
Ом Фарма (Ch)
Ом Фарма
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ом Фарма (Ch), Ом Фарма filed Critical Ом Фарма (Ch)
Publication of RU2011112781A publication Critical patent/RU2011112781A/en
Application granted granted Critical
Publication of RU2500412C2 publication Critical patent/RU2500412C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Экстракт одного или более бактериальных штаммов Lactobacillus, где экстракт представляет собой растворимый экстракт, и где экстракт содержит химически модифицированные бактериальные молекулы. ! 2. Экстракт по п.1, где химически модифицированные бактериальные молекулы получены в результате воздействия щелочной среды на один или более бактериальных штаммов Lactobacillus. ! 3. Экстракт по п.1, где экстракт обладает иммуномодулирующей активностью у индивидуума. ! 4. Экстракт по п.3, где экстракт обладает иммуностимулирующей активностью у индивидуума. ! 5. Экстракт по п.3, где экстракт обладает противовоспалительной активностью у индивидуума. ! 6. Экстракт по п.1, где один или более бактериальных штаммов Lactobacillus содержит один или более из Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus johnsonii, Lactobacillus helveticus, Lactobacillus casei defensis, Lactobacillus casei ssp. casei, Lactobacillus paracasei, Lactobacillus bulgaricus, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus salivarius, Lactobacillus lactis и Lactobacillus delbrueckii. ! 7. Экстракт по п.1, где один или более бактериальных штаммов Lactobacillus содержит один или более из Lactobacillus fermentum I-3929, Lactobacillus rhamnosus 71.38, Lactobacillus plantarum 71.39, Lactobacillus johnsonii 103782 и Lactobacillus helveticus 103146. ! 8. Экстракт по п.1, где один или более из аспарагиновой кислоты, глутаминовой кислоты, серина, гистидина, аланина, аргинина, тирозина, метионина, фенилаланина и лизина в указанном экстракте рацемизированы, по меньшей мере, на 10%. ! 9. Экстракт по п.1, где экстракт способен достигать рассчитываемого соотношения IL10/IL12 в мононуклеарных клетках периферической крови человека, причем указанное соотношение равно или больше, чем соотношение IL10/IL12, достигаемое живым штаммом Lactobacillus, из которого получен экстракт. ! 10. Экс� 1. An extract of one or more bacterial strains of Lactobacillus, where the extract is a soluble extract, and where the extract contains chemically modified bacterial molecules. ! 2. The extract according to claim 1, where the chemically modified bacterial molecules are obtained by exposure to an alkaline environment on one or more bacterial strains of Lactobacillus. ! 3. The extract according to claim 1, where the extract has immunomodulatory activity in an individual. ! 4. The extract according to claim 3, where the extract has immunostimulating activity in an individual. ! 5. The extract according to claim 3, where the extract has anti-inflammatory activity in an individual. ! 6. The extract according to claim 1, where one or more bacterial strains of Lactobacillus contains one or more of Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus johnsonii, Lactobacillus helveticus, Lactobacillus casei defensis, Lactobacillus casei. casei, Lactobacillus paracasei, Lactobacillus bulgaricus, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus salivarius, Lactobacillus lactis and Lactobacillus delbrueckii. ! 7. The extract according to claim 1, where one or more bacterial strains of Lactobacillus contains one or more of Lactobacillus fermentum I-3929, Lactobacillus rhamnosus 71.38, Lactobacillus plantarum 71.39, Lactobacillus johnsonii 103782 and Lactobacillus helveticus 103146.! 8. The extract according to claim 1, where one or more of aspartic acid, glutamic acid, serine, histidine, alanine, arginine, tyrosine, methionine, phenylalanine and lysine in the extract are racemicized by at least 10%. ! 9. The extract according to claim 1, where the extract is able to achieve the calculated ratio of IL10 / IL12 in mononuclear cells of human peripheral blood, and the ratio is equal to or greater than the ratio of IL10 / IL12 achieved by the live strain of Lactobacillus from which the extract is obtained. ! 10. Ex

Claims (21)

1. Экстракт одного или более бактериальных штаммов Lactobacillus, где экстракт представляет собой растворимый экстракт, и где экстракт содержит химически модифицированные бактериальные молекулы.1. An extract of one or more bacterial strains of Lactobacillus, where the extract is a soluble extract, and where the extract contains chemically modified bacterial molecules. 2. Экстракт по п.1, где химически модифицированные бактериальные молекулы получены в результате воздействия щелочной среды на один или более бактериальных штаммов Lactobacillus.2. The extract according to claim 1, where the chemically modified bacterial molecules are obtained by exposure to an alkaline environment on one or more bacterial strains of Lactobacillus. 3. Экстракт по п.1, где экстракт обладает иммуномодулирующей активностью у индивидуума.3. The extract according to claim 1, where the extract has immunomodulatory activity in an individual. 4. Экстракт по п.3, где экстракт обладает иммуностимулирующей активностью у индивидуума.4. The extract according to claim 3, where the extract has immunostimulating activity in an individual. 5. Экстракт по п.3, где экстракт обладает противовоспалительной активностью у индивидуума.5. The extract according to claim 3, where the extract has anti-inflammatory activity in an individual. 6. Экстракт по п.1, где один или более бактериальных штаммов Lactobacillus содержит один или более из Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus johnsonii, Lactobacillus helveticus, Lactobacillus casei defensis, Lactobacillus casei ssp. casei, Lactobacillus paracasei, Lactobacillus bulgaricus, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus salivarius, Lactobacillus lactis и Lactobacillus delbrueckii.6. The extract according to claim 1, where one or more bacterial strains of Lactobacillus contains one or more of Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus johnsonii, Lactobacillus helveticus, Lactobacillus casei defensis, Lactobacillus casei defensis, Lactobacillus casei defensis. casei, Lactobacillus paracasei, Lactobacillus bulgaricus, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus salivarius, Lactobacillus lactis and Lactobacillus delbrueckii. 7. Экстракт по п.1, где один или более бактериальных штаммов Lactobacillus содержит один или более из Lactobacillus fermentum I-3929, Lactobacillus rhamnosus 71.38, Lactobacillus plantarum 71.39, Lactobacillus johnsonii 103782 и Lactobacillus helveticus 103146.7. The extract according to claim 1, where one or more bacterial strains of Lactobacillus contains one or more of Lactobacillus fermentum I-3929, Lactobacillus rhamnosus 71.38, Lactobacillus plantarum 71.39, Lactobacillus johnsonii 103782 and Lactobacillus helveticus 103146. 8. Экстракт по п.1, где один или более из аспарагиновой кислоты, глутаминовой кислоты, серина, гистидина, аланина, аргинина, тирозина, метионина, фенилаланина и лизина в указанном экстракте рацемизированы, по меньшей мере, на 10%.8. The extract according to claim 1, where one or more of aspartic acid, glutamic acid, serine, histidine, alanine, arginine, tyrosine, methionine, phenylalanine and lysine in said extract are racemicized by at least 10%. 9. Экстракт по п.1, где экстракт способен достигать рассчитываемого соотношения IL10/IL12 в мононуклеарных клетках периферической крови человека, причем указанное соотношение равно или больше, чем соотношение IL10/IL12, достигаемое живым штаммом Lactobacillus, из которого получен экстракт.9. The extract according to claim 1, where the extract is able to achieve the calculated ratio of IL10 / IL12 in mononuclear cells of human peripheral blood, and the ratio is equal to or greater than the ratio of IL10 / IL12 achieved by the living strain of Lactobacillus from which the extract is obtained. 10. Экстракт по п.1, где экстракт уменьшает число эозинофильных клеток, число нейтрофильных клеток, число лимфоцитарных клеток или любой их комбинации у страдающих астмой мышей на фактор, по меньшей мере, 1,5 относительно страдающего астмой не леченого контроля.10. The extract according to claim 1, where the extract reduces the number of eosinophilic cells, the number of neutrophilic cells, the number of lymphocyte cells or any combination thereof in asthmatic mice by a factor of at least 1.5 relative to an untreated asthma control. 11. Способ получения экстракта по п.1, включающий:11. The method of obtaining the extract according to claim 1, including: (a) культивирование одного или более бактериальных штаммов Lactobacillus в культуральной среде;(a) culturing one or more bacterial strains of Lactobacillus in a culture medium; (b) воздействие щелочной среды на каждый бактериальный штамм Lactobacillus; и(b) the effect of an alkaline environment on each bacterial strain of Lactobacillus; and (c) обработку продукта стадии (b) для удаления нерастворимого и имеющего форму частиц материала.(c) treating the product of step (b) to remove insoluble and particulate material. 12. Способ по п.11, где стадия (c) выполняется фильтрацией в тангенциальном потоке.12. The method according to claim 11, where stage (c) is performed by filtering in a tangential flow. 13. Способ по п.11, где стадия (b) предусматривает воздействие на каждый бактериальный штамм Lactobacillus pH больше, чем 9,0, достаточное для химической модификации бактериальных молекул.13. The method according to claim 11, where stage (b) comprises exposing each bacterial strain of Lactobacillus to a pH of greater than 9.0, sufficient for chemical modification of the bacterial molecules. 14. Способ по п.11, кроме того, включающий обработку каждого штамма при pH менее чем 4,5 после стадии (b) и перед стадией (c).14. The method according to claim 11, further comprising treating each strain at a pH of less than 4.5 after step (b) and before step (c). 15. Способ по п.11, где химическая модификация включает рацемизацию одного или более из аспарагиновой кислоты, глутаминовой кислоты, серина, гистидина, аланина, аргинина, тирозина, метионина, фенилаланина и лизина в экстракте, по меньшей мере, на 10%.15. The method according to claim 11, where the chemical modification includes racemization of one or more of aspartic acid, glutamic acid, serine, histidine, alanine, arginine, tyrosine, methionine, phenylalanine and lysine in the extract by at least 10%. 16. Нутрицевтическая композиция или фармацевтическая композиция, содержащая экстракт по п.1.16. Nutraceutical composition or pharmaceutical composition containing the extract according to claim 1. 17. Способ уменьшения, по меньшей мере, одного симптома, связанного, по меньшей мере, с одним состоянием, выбранным из респираторного расстройства, аллергического состояния, расстройства мочевых путей и пищеварительного расстройства, включающий введение индивидууму терапевтически эффективного количества экстракта по п.1.17. A method of reducing at least one symptom associated with at least one condition selected from a respiratory disorder, an allergic condition, an urinary tract disorder, and a digestive disorder, comprising administering to a subject a therapeutically effective amount of an extract according to claim 1. 18. Способ по п.17, где индивидуум представляет собой человека или домашнее животное.18. The method according to 17, where the individual is a human or pet. 19. Изолированный штамм микроорганизма Lactobacillus fermentum I-3929.19. An isolated strain of the microorganism Lactobacillus fermentum I-3929. 20. Экстракт, полученный из штамма по п.19.20. The extract obtained from the strain according to claim 19. 21. Экстракт по п.20, где экстракт представляет собой растворимый экстракт. 21. The extract according to claim 20, where the extract is a soluble extract.
RU2011112781/15A 2008-09-04 2008-09-04 IMMUNOMODULATORY EXTRACTS OF BACTERIA Lactobacillus AND METHODS FOR PREPARING AND USING THEM RU2500412C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/010350 WO2010027344A1 (en) 2008-09-04 2008-09-04 Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof

Publications (2)

Publication Number Publication Date
RU2011112781A true RU2011112781A (en) 2012-10-10
RU2500412C2 RU2500412C2 (en) 2013-12-10

Family

ID=41797341

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011112781/15A RU2500412C2 (en) 2008-09-04 2008-09-04 IMMUNOMODULATORY EXTRACTS OF BACTERIA Lactobacillus AND METHODS FOR PREPARING AND USING THEM

Country Status (11)

Country Link
JP (1) JP2012502026A (en)
KR (1) KR20110051268A (en)
CN (1) CN102143756A (en)
AU (1) AU2008361375B2 (en)
BR (1) BRPI0822997A2 (en)
CA (1) CA2733249A1 (en)
IL (1) IL211041A0 (en)
MX (1) MX2011002080A (en)
RU (1) RU2500412C2 (en)
WO (1) WO2010027344A1 (en)
ZA (1) ZA201100899B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012103637A1 (en) * 2011-02-02 2012-08-09 Justbio Inc. Functional foods and beverages with synergistic properties to promote homeostasis
US9309492B2 (en) * 2011-03-29 2016-04-12 Nestec S.A. Derivative of the Lactobacilus johnsonii strain CNCM I-1225, deficient in D-lactic acid production and with an improved shelf life
CN103649306B (en) * 2011-03-29 2015-07-01 雀巢产品技术援助有限公司 Natural derivative of the lactobacilus johnsonii strain cncm I-1225, deficient in d-lactic acid production and with a further improved immune profile
US20130022586A1 (en) 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
AU2013209887B2 (en) 2012-01-16 2021-02-18 Elizabeth Mckenna Compositions and methods for the treatment of hepatic diseases and disorders
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
JP2015535829A (en) 2012-09-21 2015-12-17 マッケーナ、エリザベス Naturally occurring CpG oligonucleotide compositions and therapeutic applications thereof
US20150017208A1 (en) * 2013-07-12 2015-01-15 National Yang-Ming University Lactic acid bacterium having immunomodulatory and anti-allergic effects
JP6821643B2 (en) * 2013-09-26 2021-01-27 雪印メグミルク株式会社 Immune disease preventive agent
JP6491422B2 (en) * 2013-09-26 2019-03-27 雪印メグミルク株式会社 Immune disease preventive
CN103798392B (en) * 2014-03-07 2015-12-30 内蒙古伊利实业集团股份有限公司 Probiotic food composition and food with effect of relieving throat inflammation
KR101627806B1 (en) * 2014-06-23 2016-06-07 한국식품연구원 The culturing method for increasing immune-enhancing activity in Lactobacillus spp.
JP6940305B2 (en) * 2017-06-01 2021-09-22 株式会社明治 How to make cheese flavored ingredients
KR102335710B1 (en) 2017-10-31 2021-12-07 (주)아모레퍼시픽 Immunomodulatory composition comprising extracellular vesicles derived from lactic acid bacteria
TWI731209B (en) * 2018-01-09 2021-06-21 柯順議 Probiotics composition and uses thereof
MX2020011916A (en) 2018-05-09 2021-04-13 Ko Biolabs Inc LACTOBACILLUS PARACASEI STRAIN AND USE THEREOF.
CN112469403A (en) * 2018-06-07 2021-03-09 国立大学法人金泽大学 Pharmaceutical composition for preventing or treating kidney injury
CN112469404A (en) * 2018-06-07 2021-03-09 国立大学法人金泽大学 Pharmaceutical composition for preventing or treating kidney injury
CN109007842A (en) * 2018-10-29 2018-12-18 广州普维君健药业有限公司 Have effects that prevent and treat the probiotic composition of allergy and its application
KR102156829B1 (en) * 2019-02-22 2020-09-18 가톨릭대학교 산학협력단 Composition for preventing or treating immune diseases comprising mixture of Microbiome
CN109628359B (en) * 2019-02-22 2021-03-02 江南大学 A strain of Lactobacillus reuteri that can relieve allergic asthma and its application
EP3937957A1 (en) 2019-03-14 2022-01-19 OM Pharma SA Process for making stable bacterial extracts and their use as pharmaceuticals
CN110643541B (en) * 2019-10-25 2021-08-24 江南大学 A Lactobacillus casei that can regulate the balance of Th2/Th1 in allergic asthma and its application
CN111053789A (en) * 2019-11-26 2020-04-24 湖南营养树生物科技有限公司 Methods and compositions for modulating the immune system
AU2021207295A1 (en) * 2020-01-13 2022-08-04 Monash University Compositions and methods
CN111548961A (en) * 2020-05-15 2020-08-18 郑州和合生物工程技术有限公司 Probiotic composition for improving allergic diseases, probiotic composition powder, preparation method and application
WO2021248111A1 (en) * 2020-06-06 2021-12-09 Quorum Innovations, Llc Materials and methods for inhibiting a viral infection, including a coronavirus infection
CN111991428A (en) * 2020-06-12 2020-11-27 郑州和合生物工程技术有限公司 Probiotic composition with asthma improving effect and preparation method thereof
CN112057479B (en) * 2020-11-16 2021-02-12 河北一然生物科技有限公司 Probiotic composition capable of relieving diarrhea caused by antibiotics
KR102424594B1 (en) * 2020-11-30 2022-07-25 파이토지노믹스 주식회사 Lactobacillus fermentum OKBL-L.FE 1 strain having anti-inflammatory activity and antimicrobial activity against pathogenic microorganism and uses thereof
JP7723917B2 (en) * 2021-05-11 2025-08-15 スノーデン株式会社 Method for producing toll-like receptor 2 binding substance
KR20230001127A (en) 2021-06-28 2023-01-04 농업회사법인 산청바이오진생마을 주식회사 Method for manufacturing ginseng sprout
WO2023167563A1 (en) * 2022-03-03 2023-09-07 한국생명공학연구원 Composition containing n-carbamyl-l-glutamic acid for treatment of inflammatory diseases
CN114774302B (en) * 2022-03-09 2023-06-16 善恩康生物科技（苏州）有限公司 Application of lactobacillus plantarum CQPC02 in preparation of product for preventing and/or treating lupus nephritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH532903A (en) * 1971-06-25 1973-01-31 Nestle Sa Process of extracting proteins from cells of microorganisms
JP3004890B2 (en) * 1995-03-28 2000-01-31 雪印乳業株式会社 Pathogen infection protective agent
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
RU2302458C2 (en) * 2001-07-26 2007-07-10 Элиментери Хелс Лимитед Lactobacillus salivarius probiotic strain (variants), probiotic preparation based on the same, and method for treatment or prevention using lactobacillus salivarius strains
PE20030274A1 (en) * 2001-07-26 2003-05-08 Alimentary Health Ltd LACTOBACILLUS SALIVARIUS STRAINS
US7025998B2 (en) * 2003-05-30 2006-04-11 Rotta Research Laboratorium S.P.A. Phytoestrogens and probiotic for women's health
WO2005091933A2 (en) * 2004-03-04 2005-10-06 E-L Management Corporation Skin treatment method with lactobacillus extract
JP4938005B2 (en) * 2005-05-31 2012-05-23 ザ・アイムス・カンパニー Lactobacillus, a feline probiotic
JP2007269737A (en) * 2006-03-31 2007-10-18 Morinaga Milk Ind Co Ltd Interleukin production regulator, pharmaceutical composition and food / beverage products containing the interleukin production regulator, and method for producing the same
JP5019961B2 (en) * 2006-06-26 2012-09-05 株式会社ヤクルト本社 Interleukin 10 production promoter

Also Published As

Publication number Publication date
MX2011002080A (en) 2011-03-29
CN102143756A (en) 2011-08-03
CA2733249A1 (en) 2010-03-11
KR20110051268A (en) 2011-05-17
ZA201100899B (en) 2012-05-30
AU2008361375A1 (en) 2010-03-11
BRPI0822997A2 (en) 2015-06-23
JP2012502026A (en) 2012-01-26
IL211041A0 (en) 2011-04-28
WO2010027344A1 (en) 2010-03-11
AU2008361375B2 (en) 2014-05-22
RU2500412C2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
RU2011112781A (en) IMMUNOMODULATING EXTRACTS FROM THE LACTOBACILLUS BACTERIA, METHODS FOR PRODUCING AND USING THEM
CN111511379B (en) Composition based on probiotics and application thereof
Zeng et al. Cutting edge: probiotics and fecal microbiota transplantation in immunomodulation
CN103796660B (en) More bacterial preparations and the method for obtaining it
KR101764412B1 (en) Functionally hydrated hyaluronic acid and method of preparing coating lactic acid bacteria improving mucosal adhesive capacity and having selective antagonism in microflora
Yu et al. A novel strain of Lactobacillus mucosae isolated from a Gaotian villager improves in vitro and in vivo antioxidant as well as biological properties in D-galactose-induced aging mice
CN112877233B (en) Lactobacillus helveticus strain and application thereof
CN117106628B (en) Lactobacillus acidophilus LA15 with immunoregulation capability and application, product and method thereof
Matsumoto et al. Anti-inflammatory metabolite production in the gut from the consumption of probiotic yogurt containing Bifidobacterium animalis subsp. lactis LKM512
MX2007001863A (en) Lactobacillus rhamnosus with body-fat reducing activity and the foods containing them.
US20250051717A1 (en) Process for producing dried lactobacillus cells
CN115029260B (en) A kind of Lactobacillus gasseri with anti-inflammation and anti-oxidation properties and its application
CN117305171A (en) A strain of Bifidobacterium breve and its application
CN102216444A (en) Blood cholesterol-lowering strain of Lactobacillus delbrueckii
CN110229769B (en) Multifunctional lactobacillus fermentum CCFM1051 for relieving PFOA toxic action, fermented food and application thereof
CN116650539A (en) A kind of bifidobacteria that improves learning and memory function and its application
Hu et al. Lactobacillus reuteri biofilms inhibit pathogens and regulate microbiota in in vitro fecal fermentation
CN111088184A (en) Enterococcus faecium CCFM1106, its feed additive and its application
KR20220148723A (en) Method for producing GABA and low molecular weight collagen using Lactobacillus brevis BJ-20 (KCTC11377BP), composition for improving skin barrier damage and composition for improving sleep activity including the same
Li et al. Immunomodulatory effects of L. helveticus WHH2580 fermented milk on an immunosuppressed murine model
CN120442437A (en) Lactobacillus paracasei HNGD-AL1 for degrading sulfur-containing amino acids, bacterial agent, and application thereof in improving ulcerative colitis
CN102100704A (en) Composition and application of probiotic strain GM-080 for treating cardiac inflammation and cardiac cell apoptosis
TWI406665B (en) Medicinal composition including probiotic strain gm-080 for use in treatment of cardiac inflammation and apoptosis
Meena et al. Specific immune response of oral administration of Dahi and milk fermented with Lactobacillus helveticus against Salmonella enteritidis in mice
CN117813372A (en) Novel lactobacillus paracasei ATG-E1strain or composition for preventing or treating respiratory diseases comprising the same

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140905